Abstract:ObjectiveTo explore change of serum monocyte chemoattractant protein-1 (MCP-1)level in obese patients with type 2 diabetes mellitus(T2DM)and its relationship with atherosclerosis(AS).MethodsFrom January 2015 to August 2016,30 patients newly diagnosed as T2DM in obesity(T2DM obesity group,BMI≥28.0 kg/m2),30 patients in moderate size(T2DM non-obesity group,18.5 kg/m2≤BMI<24.0 kg/m2),and 30 healthy participants after physical examinations (NC group,18.5 kg/m2≤BMI<24.0 kg/m2).The levels of serum MCP-1 and other experimental indexes in empty stomach in each group were tested.Homeostasis model assessment of insulin resistance(HOMA-IR),insulin sensitivity index(ISI), and atherogenic index of plasma(AIP)were calculated.ResultsThe①levels of serum MCP-1 in the T2DM obesity group and T2DM non-obesity group were both much higher than that in the NC group.Serum MCP-1 in the T2DM obesity group was high than that in the T2DM non-obesity group with a statistical difference(P<0.05).②Correlation analysis indicated that serum MCP-1 had positive relationships with body mass index(BMI),triglyceride(TG),total cholesterol(TC), fasting plasma glucose(FPG),HOMA-IR and AIP(P<0.05).Serum MCP-1 was in a negative relationship with high-density lipoprotein cholesterol(HDL-C)or ISI(P<0.05).③With regard to multiple stepwise regression analysis,it was indicated BMI,TC,FPG,and AIP were all enrolled into the regression equation based on the dependent variable of MCP-1 (P<0.05).ConclusionMCP-1 is one of the key factors to promote occurrence and development of AS and IR.By testing the level of MCP-1 and implementing the corresponding intervention,it can relieve the degree of IR and AS.It is expected that MCP-1 will become a new cutting target for the treatment of macrovascular and microvascular complications in T2DM.
王慧慧;闫晓光;于修楠;张海军;孙哲. 肥胖2型糖尿病患者血清MCP-1水平变化及其与AS的关系研究[J]. 中国当代医药, 2017, 24(2): 39-41.
WANG Hui-hui;YAN Xiao-guang;YU Xiu-nan;ZHANG Hai-jun;SUN Zhe. Research on change of serum MCP-1 level in obese patients with type 2 diabetes and its relationship with AS. 中国当代医药, 2017, 24(2): 39-41.
Chen S,Hong SW,Iglesias-de la Cruz MC,et al.The key role of the transforming growth factor-beta system in the pathogenesis of diabetic nephropathy[J].Ren Fail,2001,23(3-4):471-481.
Morita T,Okada M,Yamawaki H.Mechanisms underlying a decrease in KCl-induced contraction after long-term serum-free organ culture of rat isolated mesenteric artery[J]. J Vet Med Sci,2014,76(7):963-969.
[10]
Woollard KJ,Geissmann F.Monocytes in atherosclerosis:subsets and functions[J].Nat Rev Cardiol,2010,7(2):77-86.
[11]
Uchida E,Anan F,Masaki T,et al.Monocyte chemoattractant protein-1 is associated with silent cerebral infarction in patients on haemodialysis[J].Intern Med J,2012,42(1):29-34.
Mathiesen EB,Johnsen SH,Wilsgaard T,et al.Carotid plaque area and intima-media thickness in prediction of first-ever ischemic stroke:a 10-year follow-up of 6584 men and women:the Tromsø Study[J].Stroke,2011,42(4):972-978.
[14]
Takayama S,Kawamoto R,Kusunoki T,et al.Uric acid is an independent risk factor for carotid atherosclerosis in a Japanese elderly population without metabolic syndrome[J]. Cardiovasc Diabetol,2012,11:2.
[15]
Baldwin W,McRae S,Marek G,et al.Hyperuricemia as a mediator of the proinflammatory endocrine imbalance in the adipose tissue in a murine model of the metabolic syndrome[J].Diabetes,2011,60(4):1258-1269.